These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27515536)

  • 1. Cushing's Syndrome and Steroid Dementia.
    Bernini G; Tricò D
    Recent Pat Endocr Metab Immune Drug Discov; 2016; 10(1):50-55. PubMed ID: 27515536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical Management of Cushing's Syndrome: Current and Emerging Treatments.
    Hinojosa-Amaya JM; Cuevas-Ramos D; Fleseriu M
    Drugs; 2019 Jun; 79(9):935-956. PubMed ID: 31098899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug design strategies for Cushing's syndrome.
    Usanov SA; Kliuchenovich AV; Strushkevich NV
    Expert Opin Drug Discov; 2019 Feb; 14(2):143-151. PubMed ID: 30572739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
    Fleseriu M; Castinetti F
    Pituitary; 2016 Dec; 19(6):643-653. PubMed ID: 27600150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychiatric disorders in Cushing's syndrome.
    Pereira AM; Tiemensma J; Romijn JA
    Neuroendocrinology; 2010; 92 Suppl 1():65-70. PubMed ID: 20829621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.
    Fleseriu M; Molitch ME; Gross C; Schteingart DE; Vaughan TB; Biller BM
    Endocr Pract; 2013; 19(2):313-26. PubMed ID: 23337135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychiatric and neurocognitive consequences of endogenous hypercortisolism.
    Piasecka M; Papakokkinou E; Valassi E; Santos A; Webb SM; de Vries F; Pereira AM; Ragnarsson O
    J Intern Med; 2020 Aug; 288(2):168-182. PubMed ID: 32181937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
    Fleseriu M; Biller BM; Findling JW; Molitch ME; Schteingart DE; Gross C;
    J Clin Endocrinol Metab; 2012 Jun; 97(6):2039-49. PubMed ID: 22466348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spontaneous hypercortisolism without Cushing's syndrome.
    Vingerhoeds AC; Thijssen JH; Schwarz F
    J Clin Endocrinol Metab; 1976 Nov; 43(5):1128-33. PubMed ID: 186477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclinical Cushing's syndrome is a potential cause of metabolic dementia and rapidly progressive Alzheimer-type dementia.
    Guldiken S; Guldiken B
    Med Hypotheses; 2008 Nov; 71(5):703-5. PubMed ID: 18801622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic compounds for Cushing's syndrome: a patent review (2012-2016).
    Ma L; Yin L; Hu Q
    Expert Opin Ther Pat; 2016 Nov; 26(11):1307-1323. PubMed ID: 27454103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs in the medical treatment of Cushing's syndrome.
    Schteingart DE
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affective alterations in patients with Cushing's syndrome in remission are associated with decreased BDNF and cortisone levels.
    Valassi E; Crespo I; Keevil BG; Aulinas A; Urgell E; Santos A; Trainer PJ; Webb SM
    Eur J Endocrinol; 2017 Feb; 176(2):221-231. PubMed ID: 27932530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etomidate infusion in the critical care setting for suppressing the acute phase of Cushing's syndrome.
    Dabbagh A; Sa'adat N; Heidari Z
    Anesth Analg; 2009 Jan; 108(1):238-9. PubMed ID: 19095856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic Cushing's syndrome: an overview.
    Mantero F; Scaroni CM; Albiger NM
    Pituitary; 2004; 7(4):203-7. PubMed ID: 16132199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mifepristone for management of Cushing's syndrome.
    Morgan FH; Laufgraben MJ
    Pharmacotherapy; 2013 Mar; 33(3):319-29. PubMed ID: 23436494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mifepristone: treatment of Cushing's syndrome.
    Sartor O; Cutler GB
    Clin Obstet Gynecol; 1996 Jun; 39(2):506-10. PubMed ID: 8734015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone.
    Castinetti F; Conte-Devolx B; Brue T
    Neuroendocrinology; 2010; 92 Suppl 1():125-30. PubMed ID: 20829633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cognitive effects of glucocorticoid excess in Cushing's syndrome.
    Forget H; Lacroix A; Bourdeau I; Cohen H
    Psychoneuroendocrinology; 2016 Mar; 65():26-33. PubMed ID: 26708069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cushing's syndrome: an update on current pharmacotherapy and future directions.
    Creemers SG; Hofland LJ; Lamberts SW; Feelders RA
    Expert Opin Pharmacother; 2015; 16(12):1829-44. PubMed ID: 26133755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.